New cocktail aims to wipe out CLL early
NCT ID NCT01723839
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of chemotherapy (FCR) plus the drug lenalidomide in 21 people with previously untreated chronic lymphocytic leukemia (CLL). The goal was to see if adding lenalidomide could help more patients achieve a complete response, meaning no signs of cancer remain. Participants received 4 to 6 cycles of the combo, followed by lenalidomide alone as maintenance. The study is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FCR chemotherapy (fludarabine, cyclophosphamide, rituximab) plus lenalidomide
- What this could lead to
- If successful, this combination could improve the chance of wiping out all signs of CLL after initial treatment, potentially leading to longer remission without needing ongoing therapy.
- What could go wrong
- This is a small, early-phase trial with only 21 people, so results may not apply to everyone. The treatment can cause serious side effects like low white blood cell counts (neutropenia), and lenalidomide may add extra risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
John Theurer Cancer Center at HackensackUMC
Hackensack, New Jersey, 07601, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can 3D-Printed models unlock personalized blood cancer therapies?
- Could a protein blocker quiet Leukemia's alarm system?
- Supercharged immune cells take aim at cancer and viruses in one shot
- Leukemia drug study probes thinking and memory side effects
- Smart blood pressure cuffs could protect cancer patients from heart risks
- New drug takes aim at Hard-to-Treat blood cancers